Skip to main content

Advertisement

SpringerLink
Log in

Comparison of the Efficacy and Renal Safety of Bisphosphonate Between Low-Dose/High-Frequency and High-Dose/Low-Frequency Regimens in a Late-Stage Chronic Kidney Disease Rat Model

  • Original Research
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

The efficacy and renal safety of low-dose/high-frequency (LDHF) dosing and high-dose/low-frequency (HDLF) dosing of bisphosphonates (BPs) are comparable in patients with normal kidney function but might be different in patients with late-stage chronic kidney disease (CKD). This study aimed to compare the efficacy and renal safety of two different dosage regimens of a BP, alendronate (ALN), in stage 4 CKD using a rat model. Male, 10-week-old Sprague–Dawley rats were subjected to either 5/6 nephrectomy or sham surgery. The animals received subcutaneous administration of vehicle (daily) or ALN in LDHF dosage regimen (LDHF-ALN: 0.05 mg/kg/day) or HDLF dosage regimen (HDLF-ALN: 0.70 mg/kg/2 weeks). Medications commenced at 20 weeks of age and continued for 10 weeks. Micro-computed tomography, histological analysis, infrared spectroscopic imaging, and serum and urine assays were performed to examine the efficacy and renal safety of the ALN regimens. Both LDHF-ALN and HDLF-ALN increased bone mass, improved micro-structure, and enhanced mechanical properties, without causing further renal impairment in CKD rats. Histologically, however, HDLF-ALN more efficiently suppressed bone turnover, leading to more mineralized trabecular bone, than LDHF-ALN in CKD rats, whereas such differences between LDHF-ALN and HDLF-ALN were not observed in sham rats. Both LDHF-ALN and HDLF-ALN showed therapeutic effects on high bone turnover osteoporosis in CKD stage 4 rats without causing further renal impairment. However, as HDLF-ALN more efficiently suppressed bone turnover than LDHF-ALN in late-stage CKD, HDLF-ALN might be more appropriate than LDHF-ALN for fracture prevention in high bone turnover osteoporosis patients with late-stage CKD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Seedor JG, Quartuccio HA, Thompson DD (1991) The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res 6:339–346

    CAS  PubMed  Google Scholar 

  2. Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M, Arizono H, Nagata K, Santora AC, Shiraki M, Fukunaga M, Tomomitsu T, Ohashi Y, Nakamura T (2005) Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab 23:382–388

    CAS  PubMed  Google Scholar 

  3. Recker RR, Ste-Marie LG, Chavassieux P, McClung MR, Lundy MW (2015) Bone safety with risedronate: histomorphometric studies at different dose levels and exposure. Osteoporos Int 26:327–337

    CAS  PubMed  Google Scholar 

  4. Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75–85

    CAS  PubMed  Google Scholar 

  5. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M, Research ASfBaM (2010) A typical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294

    Google Scholar 

  6. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735–1744

    CAS  PubMed  Google Scholar 

  7. Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C (2000) Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58:396–399

    CAS  PubMed  Google Scholar 

  8. Nickolas TL, McMahon DJ, Shane E (2006) Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 17:3223–3232

    PubMed  Google Scholar 

  9. Ensrud KE, Lui LY, Taylor BC, Ishani A, Shlipak MG, Stone KL, Cauley JA, Jamal SA, Antoniucci DM, Cummings SR, Group OFR (2007) Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 167:133–139

    Google Scholar 

  10. Naylor KL, McArthur E, Leslie WD, Fraser LA, Jamal SA, Cadarette SM, Pouget JG, Lok CE, Hodsman AB, Adachi JD, Garg AX (2014) The three-year incidence of fracture in chronic kidney disease. Kidney Int 86:810–818

    PubMed  Google Scholar 

  11. Jamal SA, Gilbert J, Gordon C, Bauer DC (2006) Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res 21:543–548

    PubMed  Google Scholar 

  12. Ensrud KE, Ewing SK, Taylor BC, Fink HA, Stone KL, Cauley JA, Tracy JK, Hochberg MC, Rodondi N, Cawthon PM, Group SoOFR (2007) Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures. J Gerontol A 62:744–751

    Google Scholar 

  13. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, (KDIGO) KDIGO (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69:1945–1953

    CAS  PubMed  Google Scholar 

  14. Svára F (2009) Chronic kidney disease-mineral and bone disorder (CKD-MBD): a new term for a complex approach. J Ren Care 35(Suppl 1):3–6

    PubMed  Google Scholar 

  15. Group KDIGOKC-MW (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl :S1–130

  16. Ketteler M (2011) Phosphate metabolism in CKD Stages 3–5: Dietary and pharmacological control. Int J Nephrol 2011:970245

    PubMed  PubMed Central  Google Scholar 

  17. Melamed ML, Thadhani RI (2012) Vitamin D therapy in chronic kidney disease and end stage renal disease. Clin J Am Soc Nephrol 7:358–365

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR (2007) Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 22:503–508

    CAS  PubMed  Google Scholar 

  19. Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S (2013) Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res 28:2049–2059

    CAS  PubMed  Google Scholar 

  20. Ota M, Takahata M, Shimizu T, Kanehira Y, Kimura-Suda H, Kameda Y, Hamano H, Hiratsuka S, Sato D, Iwasaki N (2017) Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. Osteoporos Int 28:1481–1490

    CAS  PubMed  Google Scholar 

  21. Thomsen JS, Mosekilde LI, Gasser JA (1999) Long-term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog SDZ PTS 893 and bone maintenance in retired breeder rats. Bone 25:561–569

    CAS  PubMed  Google Scholar 

  22. Komatsubara S, Mori S, Mashiba T, Nonaka K, Seki A, Akiyama T, Miyamoto K, Cao Y, Manabe T, Norimatsu H (2005) Human parathyroid hormone (1–34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femora. Bone 36:678–687

    CAS  PubMed  Google Scholar 

  23. Shimizu T, Takahata M, Kameda Y, Hamano H, Ito T, Kimura-Suda H, Todoh M, Tadano S, Iwasaki N (2014) Vitamin K-dependent carboxylation of osteocalcin affects the efficacy of teriparatide (PTH(1–34)) for skeletal repair. Bone 64:95–101

    CAS  PubMed  Google Scholar 

  24. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25:1468–1486

    PubMed  Google Scholar 

  25. Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28:2–17

    PubMed  PubMed Central  Google Scholar 

  26. Yamamoto J, Nishio S, Hattanda F, Nakazawa D, Kimura T, Sata M, Makita M, Ishikawa Y, Atsumi T (2017) Branched-chain amino acids enhance cyst development in autosomal dominant polycystic kidney disease. Kidney Int 92:377–387

    CAS  PubMed  Google Scholar 

  27. Nyengaard JR (1993) Number and dimensions of rat glomerular capillaries in normal development and after nephrectomy. Kidney Int 43:1049–1057

    CAS  PubMed  Google Scholar 

  28. Li P, Ma LL, Xie RJ, Xie YS, Wei RB, Yin M, Wang JZ, Chen XM (2012) Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure. Acta Pharmacol Sin 33:644–651

    PubMed  PubMed Central  Google Scholar 

  29. Boskey A, Pleshko Camacho N (2007) FT-IR imaging of native and tissue-engineered bone and cartilage. Biomaterials 28:2465–2478

    CAS  PubMed  Google Scholar 

  30. Farlay D, Panczer G, Rey C, Delmas PD, Boivin G (2010) Mineral maturity and crystallinity index are distinct characteristics of bone mineral. J Bone Miner Metab 28:433–445

    PubMed  PubMed Central  Google Scholar 

  31. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL (2005) Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16:520–528

    CAS  PubMed  Google Scholar 

  32. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31–38

    CAS  PubMed  Google Scholar 

  33. Gordon PL, Frassetto LA (2010) Management of osteoporosis in CKD Stages 3 to 5. Am J Kidney Dis 55:941–956

    PubMed  Google Scholar 

  34. Weinstein RS (2000) True strength. J Bone Miner Res 15:621–625

    CAS  PubMed  Google Scholar 

  35. Komatsubara S, Mori S, Mashiba T, Li J, Nonaka K, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H (2004) Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 19:999–1005

    CAS  PubMed  Google Scholar 

  36. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613–620

    CAS  PubMed  Google Scholar 

  37. Currey JD (2003) Role of collagen and other organics in the mechanical properties of bone. Osteoporos Int 14(Suppl 5):S29–36

    Google Scholar 

  38. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20:2105–2115

    CAS  PubMed  Google Scholar 

  39. Perazella MA, Markowitz GS (2008) Bisphosphonate nephrotoxicity. Kidney Int 74:1385–1393

    CAS  PubMed  Google Scholar 

  40. Pfister T, Atzpodien E, Bauss F (2003) The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 191:159–167

    CAS  PubMed  Google Scholar 

  41. Body JJ, Pfister T, Bauss F (2005) Preclinical perspectives on bisphosphonate renal safety. Oncologist 10(Suppl 1):3–7

    CAS  PubMed  Google Scholar 

  42. Swallow EA, Aref MW, Chen N, Byiringiro I, Hammond MA, McCarthy BP, Territo PR, Kamocka MM, Winfree S, Dunn KW, Moe SM, Allen MR (2018) Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease. Osteoporos Int 29:2139–2146

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Landauer AK, Mondal S, Yuya PA, Kuxhaus L (2014) Cyclic cryopreservation affects the nanoscale material properties of trabecular bone. J Biomech 47:3584–3589

    PubMed  Google Scholar 

  44. Tower RJ, Campbell GM, Müller M, Will O, Glüer CC, Tiwari S (2014) Binding kinetics of a fluorescently labeled bisphosphonate as a tool for dynamic monitoring of bone mineral deposition in vivo. J Bone Miner Res 29:1993–2003

    CAS  PubMed  Google Scholar 

  45. Jacobs SA, Harrison AM, Swerdlow SH, Foon KA, Avril N, Vidnovic N, Joyce J, DeMonaco N, McCarty KS (2009) Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin's lymphoma. Mol Imaging Biol 11:39–45

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI); Grant-in-Aid for Young Scientists B; Grant Number JP17K16670.

Funding

This work was supported by the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI); Grant-in-Aid for Young Scientists B; Grant Number JP17K16670. Grant Number 17K16670.

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15 Nishi-7, Kita-ku, Sapporo, 060-8638, Japan

    Ryo Fujita, Masahiro Ota, Dai Sato, Tomohiro Shimizu, Hideyuki Kobayashi, Norimasa Iwasaki & Masahiko Takahata

  2. Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

    Daigo Nakazawa

  3. Graduate School of Photonics Science, Chitose Institute of Science and Technology, Chitose, Hokkaido, Japan

    Hiromi Kimura-Suda & Fumiya Nakamura

Authors
  1. Ryo Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masahiro Ota
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dai Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daigo Nakazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiromi Kimura-Suda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fumiya Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomohiro Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hideyuki Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Norimasa Iwasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masahiko Takahata
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

RF, MO, and MT designed the research; RF, MO, DS, DN, HK-S, FN, TS, and HK performed the research; RF, MO, MT, and HK-S analyzed the data; RF and MT wrote the paper; and NI contributed to the interpretation of the results.

Corresponding author

Correspondence to Masahiko Takahata.

Ethics declarations

Conflict of interest

R.F., M.T., M.O., D.S., D.N., H.K-S., F.N., T.S., H.K., and N.I. declare that they have no conflicts of interest.

Ethical Approval

All animal studies were performed in accordance with protocols approved by Institutional Committee on Animal Resources.

Human and Animal Rights and Informed Consent

The Ethics Review Committee for Animal Experimentation of Hokkaido University approved the experimental protocol.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

223_2020_723_MOESM1_ESM.tif

Supplementary file1 (TIF 27659 kb) Supplemental Fig. 1　Longitudinal changes in serum level of Cre among the CKD groups. (a) Serum levels of Cre at the start of the treatment and at 10 weeks of treatment. (b) The relationship between the serum level of Cre at 20 weeks of age and at 30 weeks of age.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fujita, R., Ota, M., Sato, D. et al. Comparison of the Efficacy and Renal Safety of Bisphosphonate Between Low-Dose/High-Frequency and High-Dose/Low-Frequency Regimens in a Late-Stage Chronic Kidney Disease Rat Model. Calcif Tissue Int 107, 389–402 (2020). https://doi.org/10.1007/s00223-020-00723-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-020-00723-1

Keywords

Search

Navigation